Prognostic value of melanoma-associated antigen A9 in renal cell carcinoma
Objective. The aim of this study was to evaluate the prognostic relevance of melanoma-associated antigen (MAGE) A9 in renal cell carcinoma (RCC). Material and methods. Immunohistochemical staining for MAGE A9 was evaluated in a tissue microarray containing 587 RCC tumour tissue samples. Nuclear MAGE...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
2013
|
| In: |
Scandinavian journal of urology
Year: 2013, Volume: 47, Issue: 4, Pages: 311-322 |
| ISSN: | 2168-1813 |
| DOI: | 10.3109/00365599.2012.740070 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.3109/00365599.2012.740070
|
| Author Notes: | Gencay Hatiboglu, Maria Pritsch, Stephan Macher-Goeppinger, Margot Zöller, Johannes Huber, Axel Haferkamp, Sascha Pahernik, Nina Wagener & Markus Hohenfellner |
| Summary: | Objective. The aim of this study was to evaluate the prognostic relevance of melanoma-associated antigen (MAGE) A9 in renal cell carcinoma (RCC). Material and methods. Immunohistochemical staining for MAGE A9 was evaluated in a tissue microarray containing 587 RCC tumour tissue samples. Nuclear MAGE A9 expression was reviewed using a semiquantitative score. Follow-up has been surveyed since 1990 in a prospectively conducted tumour database. The effect of MAGE A9 expression on cancer-specific survival (CSS) was assessed by univariate and multivariate Cox regression analyses. Subgroup analyses were performed for non-metastatic and metastatic disease. Results.Median age in all patients was 63.2 years, 354 patients were male and 233 female, and 108 patients had metastatic disease. Median follow-up was 5.6 years for all patients and 9.0 years for patients still alive (range 0-19.9 years). High nuclear MAGE A9 expression was present in 326 tumour specimens (55.5%). In multivariate analyses high nuclear MAGE A9 expression was associated with poor CSS (p = 0.0027). Furthermore, tumour stage, lymph-node and distant metastasis, Fuhrman grade G3/4, Karnofsky index < 80% and male gender were associated with poor CSS. In subgroup analyses, results were concordant for patients with non-metastatic disease. In patients with metastatic disease, only Karnofsky index > 80% was a significant predictor for CSS; MAGE A9 expression could not be shown to be associated with CSS (p = 0.161). Conclusions.High nuclear MAGE A9 expression is independently associated with poor CSS in patients with non-metastatic RCC. The assessment of MAGE A9 expression can provide additional prognostic information and should be used in decision-making regarding adjuvant therapy in patients with non-metastatic disease. |
|---|---|
| Item Description: | Published online: 12 Nov 2012 Gesehen am 08.10.2021 |
| Physical Description: | Online Resource |
| ISSN: | 2168-1813 |
| DOI: | 10.3109/00365599.2012.740070 |